Evidence map›Paper›PMID 39843887›Full record

ArticleNature communications2025

Mgl2

Peter C Cook, Sheila L Brown, Emma L Houlder, Julio Furlong-Silva, Daniel P Conn, Stefano A P Colombo, Syed Baker, Freya R Svedberg, Gareth Howell, Margherita Bertuzzi and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Peter C CookMedical Research Council Centre for Medical Mycology at the University of Exeter, Department of Biosciences, Faculty of Health and Life Sciences, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom. p.c.cook@exeter.ac.uk.ORCID http://orcid.org/0000-0002-5208-4985
Sheila L BrownLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
Emma L HoulderLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.ORCID http://orcid.org/0000-0003-0448-6055
Julio Furlong-SilvaMedical Research Council Centre for Medical Mycology at the University of Exeter, Department of Biosciences, Faculty of Health and Life Sciences, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom.
Daniel P ConnMedical Research Council Centre for Medical Mycology at the University of Exeter, Department of Biosciences, Faculty of Health and Life Sciences, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom.ORCID http://orcid.org/0000-0002-4820-4227
Stefano A P ColomboLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
Syed BakerLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-6633-333X
Freya R SvedbergLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
Gareth HowellLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
Margherita BertuzziManchester Fungal Infection Group, University of Manchester, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-5900-591X
Louis BoonJJP Biologics, Warsaw, Poland.ORCID http://orcid.org/0000-0002-0937-9171
Joanne E KonkelLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-6525-5499
Christopher R ThorntonDepartment of Biosciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.ORCID http://orcid.org/0000-0001-6213-3130
Judith E AllenLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-3829-066X
Andrew S MacDonaldLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom. andrew.macdonald@ed.ac.uk.ORCID http://orcid.org/0000-0002-5356-1149

Funding

Academy of Medical Sciences SBF002/1076DH | National Institute for Health Research (NIHR) NIHR203320RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/P504543/1RCUK | Medical Research Council (MRC) MR/N006364/2RCUK | Medical Research Council (MRC) MR/P501955/2RCUK | Medical Research Council (MRC) MR/V011235/1RCUK | Medical Research Council (MRC) MR/W018748/1Wellcome TrustWellcome Trust (Wellcome) 106898/A/15/ZWellcome Trust (Wellcome) 218550/Z/19/Z
6 · The paper itself

Abstract

Fungal spores are abundant in the environment and a major cause of asthma. Originally characterised as a type 2 inflammatory disease, allergic airway inflammation that underpins asthma can also involve type 17 inflammation, which can exacerbate disease causing failure of treatments tailored to inhibit type 2 factors. However, the mechanisms that determine the host response to fungi, which can trigger both type 2 and type 17 inflammation in allergic airway disease, remain unclear. Here we find that CD11c

Indexed as

AsthmaDendritic CellsInflammationAnimalsCD11c AntigenCD4-Positive T-LymphocytesFemaleLungMiceMice, Inbred C57BLReceptors, CCR7Spores, FungalCcr7 protein, mouseCD11c AntigenReceptors, CCR7

Identifiers

PMID39843887
PMCPMC11754877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.